Research programme: reproductive health and immunology therapeutics - Santhera/Serono
Alternative Names: Reproductive health and immunology therapeutics research programme - Santhera/SeronoLatest Information Update: 12 Mar 2008
At a glance
- Originator Merck Serono; Santhera Pharmaceuticals
 - Developer Santhera Pharmaceuticals
 - Class Small molecules
 - Mechanism of Action Undefined mechanism
 
- 
          
            
              Orphan Drug Status
              No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
 
Highest Development Phases
- Discontinued Immunological disorders; Infertility
 
Most Recent Events
- 12 Mar 2008 Discontinued - Preclinical for Immunological disorders in Germany (unspecified route)
 - 12 Mar 2008 Discontinued - Preclinical for Infertility in Germany (unspecified route)
 - 05 Jan 2007 Serono has been acquired by Merck KGaA